Searchable abstracts of presentations at key conferences in endocrinology

ea0034p401 | Thyroid | SFEBES2014

The diagnosis of Graves’ disease: diagnostic and management dilemmas

Pichaipillai Lakshminarayanan , Mishra Biswa

Aim: Diagnosis of Graves’ is generally based on clinical presentation and physical examination of thyroid gland. The general assumption is that the thyroid gland is usually normal or diffusely enlarged in Graves’ disease. The aim of our retrospective observational analysis was to establish the ultrasonographic morphology of the thyroid gland in patients with Graves’ disease.Methods: We analysed the case records and biochemical investigatio...

ea0077lb46 | Late Breaking | SFEBES2021

Improvement in the delivery of Diabetes foot care after implementing a restructured referral form: An experience from a District General Hospital

Qamar Imran , Earnshaw Louise , Pichaipillai Lakshminarayanan

Background: There are nearly 5 million people with diabetes mellitus in the UK with an estimated 10% of diabetes patients developing a foot ulcer at some point in their lives. Nearly 9500 diabetes-related amputations are reported in the UK per year and approximately 80% of the NHS budget on diabetes care is spent on treating complications. Limb/life-threatening diabetic foot problems are referred to acute services immediately and all other active diabetic foot diseases are ref...

ea0037ep636 | Obesity and cardiovascular endocrinology | ECE2015

The use of intermittent 7.5 mg tolvaptan on an out-patient basis for SIADH: a retrospective audit from a tertiary cancer hospital

Kumar Mohit , Pichaipillai Lakshminarayanan , Trainer Peter , Higham Claire

Tolvaptan (a V2 receptor antagonist) is licensed for correction of hyponatraemia in patients with SIADH at an initial dose of 15 mg od. Data in oncology patients with SIADH suggest 7.5 mg can safely and effectively increase sodium levels where 15 mg can on occasion lead to too rapid a correction. Recommendations suggest a repeat sodium taken at 4–6 h. We retrospectively assessed the safety and efficacy of intermittent out-patient dosing with 7.5 mg tolv...

ea0037ep1236 | Clinical Cases–Pituitary/Adrenal | ECE2015

Accelerated sarcopenia as an initial manifestation of Cushing's disease

Pichaipillai Lakshminarayanan , Kumar Mohit , Pathmanathan Sivatharshya , Tiong Denise , Higham Claire

Introduction: Cushing’s syndrome usually presents with a phenotype including central obesity, striae, hypertension and diabetes. We report a case of Cushing’s syndrome presenting in an atypical manner.Case: A 73 year old lady was referred to neurology with a year’s history of progressive limb wasting, weakness and recurrent falls. The neurology team diagnosed accelerated sarcopenia. Investigations included CK (normal), EMG (suggested myopa...

ea0065p149 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Prolonged supervised fast for insulinoma – an experience in a District General Hospital Trust

Khan Haris , Nawaz Maimoona , Arul-Devah Vilashini , Ashraf Fahad Hassan , Pichaipillai Lakshminarayanan

Introduction: Insulinoma a neuroendocrine tumour is diagnosed by inappropriately raised Insulin concentrations during a spontaneous or induced episode of hypoglycaemia. A provocative 72-h supervised fast is done to evaluate suspected inappropriate insulin secretion. Our aim is to see if it is feasible for a shorter duration of fast is enough to confirm Insulinoma.Method and results: In our Trust we analysed retrospectively in the last 10 years, ...